1. Increasing value for money in health systems

   Editorial Pages: 91 - 94

2. The risk-adjusted vision beyond casemix (DRG) funding in Australia

   • Kathryn M. Antioch
   • Michael K. Walsh

   Original Papers Pages: 95 - 109

3. Pricing of pharmaceuticals

   • Mark J. C. Nuijten
   • Joszef Kosa

   Original Papers Pages: 110 - 115

4. The risk-adjusted vision beyond casemix (DRG) funding in Australia

   • Kathryn M. Antioch
   • Michael K. Walsh

   Erratum Pages: 115 - 115

5. Genetic screening, health care and the insurance industry

   • Diego F. Ossa
   • Adrian Towse

   Original papers Pages: 116 - 121

6. Price-cost margin in the pharmaceutical industry

   • Ismo Linnosmaa
   • Raine Hermans
   • Taru Hallinen

   Original Papers Pages: 122 - 128

7. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease

   • Thomas Hoffmann
   • Helmut Brunner

   Original Papers Pages: 129 - 135

   

8. Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients

   • Janne Martikainen
   • Hannu Valtonen
   • Tuula Pirttilä

   Original Papers Pages: 136 - 142

   

9. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine

   • Francis Fagnani
   • Camille Le Fur
   • Michel Gibergy

   Original Papers Pages: 143 - 149

   

10. An empirical analysis of the demand for physician services across the European Union

    • Sergi Jiménez-Martín
    • José M. Labeaga
    • Maite Martínez-Granado

    Pages: 150 - 165

    

11. Economic growth, longevity and the epidemiological transition

    • Olivier F. Morand

    Original papers Pages: 166 - 174

    

12. Dynamic competition in pharmaceuticals

    • Laura Magazzini
    • Fabio Pammolli
    • Massimo Riccaboni

    Invited Papers Pages: 175 - 182

    

13. The European Network of Health Economic Evaluation Databases (EURO NHEED) Project

    • John Nixon
    • Philippe Ulmann
    • Gérard de Pouvourville

    Scientific Information Pages: 183 - 187

14. “Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”

    • Nick Bansback
    • Sue Ward
    • Jon Karnon

    Commentary Pages: 188 - 189

    

15. Pricing and reimbursement of drugs in Ireland

    • Michael Barry
    • Lesley Tilson
    • Máirín Ryan

    Pricing and Reimbursement Systems Pages: 190 - 194